TIDMCLC
RNS Number : 9472E
Calculus VCT PLC
23 October 2018
Calculus VCT plc
Half Yearly Report for the six months ended 31 August 2018
INVESTMENT OBJECTIVE
The Company's principal objectives for investors are to:
-- invest in a portfolio of Venture Capital Investments that
will provide investment returns that are sufficient to allow the
Company to maximise dividends and capital growth over the medium to
long term;
-- generate sufficient returns from a portfolio of Venture
Capital Investments that will provide attractive long-term returns
within a tax efficient vehicle;
-- review the appropriate level of dividends annually to take
account of investment returns achieved and future prospects;
and
-- maintain VCT status to enable qualifying investors to retain
their income tax relief of up to 30 per cent. on the initial
investment and receive tax-free dividends and capital growth.
FINANCIAL REVIEW
Ordinary share fund
Financial Highlights 6 months to 6 Months to 12 Months to
31 August 2018 31 August 2017 28 February 2018
Total return per new
Ordinary share (1.63p) (2.46p) (2.72p)
Net asset value per
new Ordinary share 81.10p 87.54p 87.00p
To date, 8.25 pence of dividends have been paid to eligible
Ordinary shareholders. In addition, 84.05 pence has been paid to
original ordinary shareholders and 73.1 pence to original C
shareholders prior to the share class merger that took place on 1
August 2017.
CHAIRMAN'S UPDATE
I am pleased to present your Company's results for the 6 months
to 31 August 2018.
Performance summary
During the period, five investments were made on behalf of the
qualifying portfolio. In April 2018, GBP200,000 comprising equity
and loan notes was invested in Mologic Ltd, a contract research
developer in the field of Point of Care diagnostic devices. In July
2018, three qualifying investments were made: GBP150,000 follow-on
investment in Benito's Hat, a chain of Mexican restaurants;
GBP200,000 in CloudTrade Technologies which provides cloud based
e-invoicing services; and GBP200,000 in Oxford Biotherapeutics
Limited, a clinical stage oncology company with a strong pipeline
of Immuno-oncology based therapies. In August 2018, GBP208,000
comprising equity and loan notes was invested in Duvas Technologies
Limited, developer of a portable gas monitoring device which can
measure certain gases to parts per billion. Further details on
these investments can be found in the Investment Manager's Report
below.
During the period the Company redeemed the GBP150,000 loan notes
from AnTech Limited.
For the non-qualifying portfolio, the Company invested a further
GBP800,000 in each of the Goldman Sachs Sterling Liquidity Fund,
Fidelity Sterling Liquidity Fund and Aberdeen Sterling Liquidity
Fund in August 2018.
Buybacks
During the period, the Company bought back and cancelled 10,000
Ordinary shares. The Company continues to review opportunities to
carry out share buybacks at a discount of no greater than 10% to
NAV.
Dividends
A dividend was paid on 26 July 2018 of 4.0 pence per eligible
Ordinary share.
Board composition
Steve Meeks has indicated that he would like to step down from
the board on 31 December 2018. Steve has been with the Company
since inception and the board would like to thank him for the
significant contribution he has made to the VCT.
New D share/Ordinary share issue
The offer for subscription for Ordinary Shares that opened on 4
August 2017 and closed on 1 August 2018 received aggregate
subscriptions from the issue of Ordinary shares of GBP2.8
million.
At the general meeting on 9 October 2018 shareholders also
approved the launch of a further offer for subscription for
Ordinary Shares, with the shares to be issued in the 2018/19 and
2019/20 tax years.
Developments since the period end
There have been no material developments since the period
end.
INTERIM MANAGEMENT REPORT
Venture Capital Investments
Portfolio developments
Calculus Capital Limited manages the Company's portfolio of
venture capital investments. In general, we prefer investments to
be of a sufficient size to enable us to play an influential role in
helping the investee companies develop. Investments by the Company
may be by way of equity, and also by way of loan stock and/or
preference shares which provide income to assist in paying
dividends and provide a measure of risk mitigation.
As at 31 August 2018, the portfolio had twenty seven Qualifying
Investments. An update on some of the portfolio companies has been
provided below.
AnTech Limited
AnTech, a specialist engineering company in the oil and gas
market, repaid its loan note as part of a wider refinancing in
preparation for drilling operations in Saudi Arabia and the US.
C4X Discovery Holdings plc
C4X Discovery plc (C4XD) is an innovative company focusing on
the discovery, design and development of small molecule drugs. Its
drug research is a combination of advanced computer modelling and
'wet' science. Its proprietary patented platforms allow it to
analyse the dynamic 3D shape of potential drug candidates on the
basis of experimental data and to select the candidates that are
most likely to bind to the required target and least likely to bind
to alternative targets that typically cause unwanted side effects.
C4XD is building a significant portfolio of candidates in various
therapeutic areas and, in March 2018, announced its first major
licensing agreement with Indivior, receiving $10 million upfront,
potential milestones totalling $284 million and the potential of
further royalties. C4X closed a GBP10m funding round in October
2018, of which funds managed by Calculus Capital invested
GBP1.5m.
CloudTrade Limited
CloudTrade is a software company providing technology that
allows businesses to automatically process invoices, orders, and
other business documents regardless of the form in which they are
received. The core IP of the product is its patent protected
process which interprets the contents of human readable documents
(PDF, word, CSV, HTML, etc.), and then converts the information
into a data file (EDI/XML). The Company has an impressive list of
reseller partners including IBM, DXC Technology, BT and Cegedim and
impressive end users including Arco, Qantus, the Scottish
Government and the NHS. In July 2018, funds managed by Calculus
Capital invested GBP2.0m in the company which will be used to
invest in sales, marketing, delivery and finance, with the goal to
capitalise on the global market opportunity and significantly
increase sales.
Duvas Technologies Limited
Duvas develops and produces specialised emissions detection
equipment using ultra-violet (UV) spectroscopy. Duvas' highly
sensitive detection technology enables remote sensing and
identification of airborne chemicals at a "parts per billion"
level. The Duvas core technology includes software and algorithms,
together with an expanding 'gas library' of gas signatures that
allow Duvas to programme its devices to recognise such gases. The
company's first commercial, patented UV spectroscopy unit is called
the DV3000, which has obtained CE marking for sales in Europe and
is also being sold in China and the US. Duvas' primary target is
the petrochemical industry where tighter regulation is driving
demand growth.
Every1Mobile Limited
Every1Mobile has developed a modular mobile web platform through
which it offers community management services across sub-Saharan
Africa to multi-national corporates such as Unilever, international
development agencies and non-profit organisations including the
Gates' Foundation, seeking to access the fast developing SME and
consumer markets. Whilst work for corporate customers focuses on
developing business skills and financial literacy, work for NGOS
and not for profits focuses on matters such as sexual health,
family planning and nutrition. Since Calculus has invested,
Every1Mobile is performing in line with its growth plan and has won
several major new contracts (for operations in Africa and in
emerging markets outside Africa) and is, with Unilever, developing
its U Join community of store operators in Kenya and Naijacare
community of medicine vendors in Nigeria.
Mologic Limited
Mologic is developing a new generation of diagnostic devices to
improve accuracy or target diseases for which Point of Care
diagnosis is underdeveloped with its first two products having
received an EU CE mark. In addition to the product development
pipeline, the company has a number of contract research partnering
programmes utilising the team's core expertise in diagnostics
development and novel analytical techniques. Calculus funds first
invested in 2015; to support its development efforts the company
raised a further GBP3.5 million in April 2018 with funds managed by
Calculus investing GBP500,000.
Open Energy Market Limited
Open Energy Market Limited (OEM) has created an online
marketplace on which corporate energy contracts are traded,
introducing digital innovation into the antiquated, manual energy
brokerage process in order to improve transparency and decrease
energy costs for large energy users. Significant energy contracts
require a bespoke price quote from the energy suppliers due to the
large quantity of energy expected to be consumed. OEM's platform
connects business customers directly to all 16 major energy
providers of gas and electricity removing the need for a
third-party broker. The energy providers bid for contracts on the
platform via a live auction process which allows businesses to buy
energy in a streamlined and more transparent way. OEM customers
include Dairy Crest, Easyjet, Southampton Football Club and Suffolk
County Council (for public infrastructure such as street
lighting).
Origin Broadband Limited
The Company sold its holding in Origin in September 2018. Origin
Broadband, provider of internet and phone services, needed
additional funding to support its rapid growth since the Company
invested in December 2016. Funds managed by Calculus supported
further funding rounds, which included taking on a co investor in
May 2018 which relieved the stress of the balance sheet albeit at
what constituted a down round. That co investor subsequently made
an offer to acquire all Calculus' shares at a premium to the price
of the round in May 2018, which Calculus accepted. This resulted in
a loss to the Company of GBP154,254 compared to the original cost
of the investment.
Oxford BioTherapuetics Limited
Oxford BioTherapeutics (OBT) is a clinical stage oncology
company committed to the discovery and development of novel
therapies for various cancer types. OBT has a strong pipeline of
immune-oncology (IO) therapies, which are used to re-engage and
recruit the body's immune system to attack cancer cells. OBT has
agreed multiple development deals with large pharmaceutical
companies, including German company Boehringer Ingelheim and
Italy's largest pharmaceutical company, The Menarini Group, which
is fully funding the development of two clinical programmes through
to completion of Phase II. In July 2018, funds managed by Calculus
Capital invested GBP2.0m in the company which will be used to
prepare the IO pre-clinical pipeline for clinical development as
well as funding the development of further therapeutic leads.
Park Street Shipping Limited
The Company purchased a 2010 South Korean built Handysize dry
bulk vessel, the Nordic London, in February 2017 for $8.3m. MV
Nordic London is currently on a 9-11 month charter with Danish
shipping company Clipper. The company continues to trade
profitably, benefiting from a recovering dry bulk market. A
valuation by Clarksons in September 2018 valued the vessel at
$12.9m, which equates to an uplift on cost of GBP71,000 for the
Company. The increase in share price reflects improving market
conditions drawing up vessel values, and the strengthening of the
US dollar relative to the pound.
Pico's Limited ("Benito's Hat")
Benito's Hat is a Mexican-themed fast casual restaurant business
with eight sites. In 2017, under a new management team, Benito's
undertook an extensive programme to position its operating model to
reflect a changing trading and employment environment. These
changes to the supply chain and site operating model enabled the
Company to open a new site in the Highcross Shopping Centre in
Leicester. This brings the estate to eight sites. During the year
the Company closed a funding round of GBP1m from existing
shareholders including Calculus Capital. This investment will
provide funding for new site openings in a retail property market
where lease costs have 'cooled' and where there are opportunities
to acquire additional sites on attractive terms. The operational
changes and the impressive new management team, including newly
appointed Managing Director Michael Pearson (who brings experience
from Ping Pong Dim Sum, Intercontinental Hotels Group and SSP Group
Travel), will enable Benito's to grow to a size and level of
profitability attractive to trade and private equity buyers.
Solab Group Limited
Solab Group, the long established manufacturer of fragrances and
skincare products for third party brand owners, has yet to see any
improvement in difficult trading conditions. However, several new
initiatives have reduced its losses and it has secured two
significant new customers for 2019.
Synpromics Limited
Synpromics is a leader in gene control, enabling safer and more
effectively targeted medicines through proprietary genomics,
bioinformatics and intelligent data-driven design. The company has
developed PromPT(R), its multi-dimensional bioinformatics database
that enables the development of specific "promoters" for the next
generation of cell and gene-based medicines and bioprocessing
applications. The company continues to add to its collaborations
with key players in the cell and gene therapy sector including
Biomarin, Homology, Lonza, Uniqure and Solid Biosciences.
Synpromics has recently announced the grants from Scottish
Enterprise and Innovate UK which contribute over GBP2.1 million to
its R&D programme to further develop its platform and create
novel inducible promoter systems that can be applied across the
biotechnology sector.
Terrain Energy Limited
Terrain has interests in four production licences and seven
exploration licences with approximately 150 barrels of oil per day
being produced from wells on these licences (gross). A planning
issue has been resolved at Brockham and the new well will be put on
test in December. On the exploration side, Terrain owns 100% of the
Egmating licence in Germany. A geothermal well was drilled there in
2016 which encountered strong evidence of significant gas reserves.
The Directors are examining the prospect of an exit event in the
next 12 months, depending on market conditions.
Tollan Energy Limited
Tollan owns a portfolio of 325 solar photovoltaic ("PV") systems
on rooftops in Northern Ireland. The solar PV generating capacity,
which is installed on residential and some commercial roofs in the
Belfast area, benefits from Northern Ireland Renewable Obligation
Certificates (NIROCs). The systems have demonstrated stable
generation levels following the downsizing of c. 19% of the systems
in the portfolio to comply with legislation. Tollan is currently in
a period of exclusivity with a company seeking to acquire its trade
and assets with the deal likely to complete in November 2018.
Weeding Technologies Limited
Weedingtech is a cleantech company focused on replacing toxic
herbicides, particularly in the municipal market. Weedingtech's
technology treats weed and moss using environmentally friendly hot
foam (which keeps the heat on long enough to kill the weed or
moss). In August, Monsanto was ordered to pay $289 million in
damages to a cancer patient who had been regularly exposed to
glyphosate (Roundup). Whilst this verdict may be overturned on
appeal, it has increased the focus of both the media and local and
national governments on the use of glyphosate, particularly in
public places, and is resulting in increasing interest in
alternative weed control solutions, such as Weedingtech's.
Developments since the period end
In October 2018, the Company invested GBP200,000 in MIP
Diagnostics Limited. MIP Diagnostics is a novel affinity reagent
company which uses its proprietary technology to make nanoMIPs
which are versatile, robust and highly stable alternatives to
antibodies.
Also in October 2018, the Company invested GBP50,000 in drug
discovery company, C4X.
Other than as disclosed above, there have been no developments
since the period end.
Calculus Capital Limited
23 October 2018
INVESTMENT PORTFOLIO AS AT 31 AUGUST 2018
- TOTAL FUND
% of Net Assets
Unquoted - loan stock 6%
Quoted and unquoted - ordinary and
preference shares 44%
Unquoted - liquidity funds 43%
Net current assets 7%
------------------------------------ -----
100%
Asset class - % of Portfolio
Quoted and unquoted - Qualifying
Investments 54%
Unquoted - other non-Qualifying
Investments 46%
------------------------------------- -----------------------
100%
Book Cost Valuation % of
Company Nature of Business GBP'000 GBP'000 Portfolio
------------------------------------ ------------------------ ---------- ---------- ----------
Qualifying Investments
Air Leisure Group Limited Leisure 200 200 2
AnTech Limited Oil services 120 142 1
Arcis Biotechnology Holdings
Limited Med Tech 275 275 2
Blu Wireless Technology Limited Technology Hardware 150 150 1
C4X Discovery Holdings plc Pharma Services 149 154 1
CloudTrade Technologies Limited Software 200 200 2
Cornerstone Brands Limited E-commerce 150 150 1
Duvas Technologies Limited Oil & Gas Services 208 208 2
Every1Mobile Limited Technology Services 200 230 2
Genedrive plc Biotech 144 74 1
Infrastrata plc Gas Utilities 2 2 -
MicroEnergy Generation Services
Limited Energy 148 108 1
Mologic Limited Med Tech 200 200 2
Open Energy Market Limited Technology Services 200 230 2
Origin Broadband Ltd Telecommunications 226 72 1
Oxford Biotherapeutics Limited Biotech 200 200 2
Park Street Shipping Limited Shipping 150 221 2
Pico's Limited Leisure 199 181 2
Quai Administration Services
Limited Technology 220 220 2
Scancell Holdings plc Biotech 378 301 3
Solab Group Limited Cosmetics 479 475 4
Synpromics Limited BioTech 134 277 3
Terrain Energy Limited Oil & gas production 967 1,032 9
The One Place Capital Limited Personal Finance 277 277 3
Tollan Energy Limited Energy 123 135 1
Venn Life Sciences Holdings
plc Clinical research 55 16 -
Weeding Technologies Limited Technology Hardware 216 233 2
------------------------------------ ------------------------ ---------- ---------- ----------
Total Qualifying Investments 5,970 5,963 54
Other non-Qualifying Investments
------------------------------------ ------------------------ ---------- ---------- ----------
Aberdeen Sterling Liquidity
Fund Liquidity fund 1,682 1,682 15
Fidelity Sterling Liquidity
Fund Liquidity fund 1,681 1,685 16
Goldman Sachs Sterling
Liquidity Fund Liquidity fund 1,680 1,680 15
Terrain Energy Limited Oil and gas production 5 5 -
----------------------------------- ------------------------- ---------- ---------- ----------
Total Other non-Qualifying
Investments 5,048 5,052 46
------------------------------------ ------------------------ ---------- ---------- ----------
Total Investments 11,018 11,015 100
Net Current Assets less Creditors
due after one year 816
------------------------------------ ------------------------ ---------- ---------- ----------
Net Assets 11,831
------------------------------------ ------------------------ ---------- ---------- ----------
PRINCIPAL RISKS
The principal risks facing the Company remain the same as those
detailed on page 24 of the Annual Report and Accounts for the year
ended 28 February 2018.
The main risks faced by the Company include, but are not limited
to, loss of approval as a venture capital trust and other
regulatory breaches, risks of making and realising qualifying
investments, liquidity/marketability risk, changes in
legislation/taxation, engagement of third party advisers, market
price risk and credit risk.
GOING CONCERN
After making enquiries, and having reviewed the portfolio,
balance sheet and projected income and expenditure for the next
twelve months, the Directors have a reasonable expectation that the
Company has adequate resources to continue in operation for the
foreseeable future. The Directors have therefore adopted the going
concern basis in preparing these condensed financial
statements.
DIRECTORS' RESPONSIBILITY STATEMENT
The half-yearly financial report, which has not been audited or
reviewed by the Company's auditors is the responsibility of, and
has been approved by, the Directors. The Directors confirm that to
the best of their knowledge the half-yearly financial report, which
has been prepared in accordance with the UK Listing Authority
Disclosure and Transparency Rules ("DTR") and in accordance with
the Financial Reporting Council's Financial Reporting Standard 104:
'Interim Financial Reporting' gives a true and fair view of the
assets, liabilities, financial position and the net return of the
Company as at 31 August 2018.
The Directors confirm that the Chairman's Update, the Investment
Management report, the disclosures above and notes 10 and 11,
include a fair review of the information required by DTR 4.2.7R,
being an indication of important events that have occurred during
the first six months of the financial year and their impact on the
condensed set of financial statements and a description of the
principal risks and uncertainties for the remaining six months of
the financial year, and DTR 4.2.8R.
The Directors of Calculus VCT plc are:
Michael O'Higgins
Kate Cornish-Bowden
Steve Meeks
Diane Seymour-Williams
John Glencross
By order of the Board
Michael O'Higgins
Chairman
23 October 2018
CONDENSED INCOME STATEMENT
FOR THE PERIOD FROM 1 MARCH 2018 TO 31 AUGUST 2018
(UNAUDITED)
6 Months Ended 6 Months Ended 12 Months Ended
31 August 2018 31 August 2017 28 February 2018
Revenue Capital Revenue Capital Revenue Capital
---------------- ----- ---------- ---------- -------- ---------- ---------- -------- ---------- --------
Return Return Total Return Return Total Return Return Total
Note GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Investment
holding
(losses)/gains 8 - (174) (174) - 165 165 - 232 232
Gain/(loss) on
disposal
of investments 8 - 104 104 - (181) (181) - (159) (159)
Income 42 - 42 27 - 27 65 - 65
Investment
management
fee (24) (72) (96) (18) (52) (70) (39) (115) (154)
Costs of
acquiring
Neptune
Calculus
assets and
liabilities - - - - - - (55) - (55)
Other operating
expenses (93) - (93) (157) - (157) (202) - (202)
---------------- ----- ---------- ---------- -------- ---------- ---------- -------- ---------- -------- --------
Loss on
ordinary
activities
before
taxation (75) (142) (217) (148) (68) (216) (231) (42) (273)
---------------- ----- ---------- ---------- -------- ---------- ---------- -------- ---------- -------- --------
Taxation on 3 - - - - - - - - -
ordinary
activities
---------------- ----- ---------- ---------- -------- ---------- ---------- -------- ---------- -------- --------
Loss for the
period (75) (142) (217) (148) (68) (216) (231) (42) (273)
---------------- ----- ---------- ---------- -------- ---------- ---------- -------- ---------- -------- --------
Basic and
diluted
deficit
per new
Ordinary share 2 (0.56)p (1.07)p (1.63)p (1.68)p (0.78)p (2.46)p (2.30)p (0.42)p (2.72)p
---------------- ----- ---------- ---------- -------- ---------- ---------- -------- ---------- -------- --------
The supplementary revenue return and capital return columns are
both prepared in accordance with the Association of Investment
Companies ("AIC") Statement of Recommended Practice ("SORP"). No
operations were acquired or discontinued during the period. All
items in the above statements derive from continuing operations.
There were no recognised gains or losses other than those passing
through the Income Statement. The notes form an integral part of
these condensed financial statements.
CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD FROM 1 MARCH 2018 TO 31 AUGUST 2018
(UNAUDITED)
Non-distributable reserves Distributable
reserves
Share Capital Capital Capital
Share Premium Special Redemption Reserve Reserve Revenue
Capital Account Reserve Reserve Realised Unrealised Reserve Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
For the 6 month
period to 31
August 2018
1 March 2018 116 298 9,974 56 451 171 (936) 10,130
Investment holding
losses - - - - - (174) - (174)
Gain on disposal
of investments - - - - 104 - - 104
New share issue 30 2,474 - - - - - 2,504
Expense of share
issue - (90) - - - - - (90)
Share buybacks for
cancellation - - (7) - - - - (7)
Management fee
allocated to
capital - - - - (72) - - (72)
Change in accrual
in IFA Commission - (38) - - - - - (38)
Revenue return
after tax - - - - - - (75) (75)
Dividends paid
(note 9) - - (451) - - - - (451)
-------------------
31 August 2018 146 2,644 9,516 56 483 (3) (1,011) 11,831
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
For the 6 month
period to 31
August 2017
1 March 2017 141 7,046 1,277 - 725 (61) (705) 8,423
Investment holding
gains - - - - - 165 - 165
Loss on disposal
of investments - - - - (181) - - (181)
New D share issue 2 153 - - - - - 155
Expenses of D
share issue - (9) - - - - - (9)
Purchase of shares
for cancellation (55) - - 55 - - - -
Management fee
allocated to
capital - - - - (52) - - (52)
Change in accrual
in IFA Commission - (26) - - - - - (26)
Revenue return on
ordinary
activities after
tax - - - - - - (148) (148)
Dividend paid - - (601) - - - - (601)
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
31 August 2017 88 7,164 676 55 492 104 (853) 7,726
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
CONDENSED
STATEMENT OF Non-distributable
CHANGES reserves Distributable
IN EQUITY reserves
(CONTINUED)
Share Capital Capital Capital
Share Premium Special Redemption Reserve Reserve Revenue
Capital Account Reserve Reserve Realised Unrealised Reserve Total
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
For the 12 months GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
to 28 February
2018*
1 March 2017 141 7,046 1,277 - 725 (61) (705) 8,423
Investment holding
gains - - - - - 232 - 232
Loss on disposal
of investments - - - - (159) - - (159)
New share issue (D
shares) 2 153 - - - - - 155
Expense of share
issue (D shares) - (9) - - - - - (9)
Purchase of shares
for cancellation
in connection
with the merger
of classes (55) - - 55 - - - -
New share issue
(Ordinary shares
re
Neptune-Calculus
assets
and liabilities
acquisition) 25 2,176 3 - - - - 2,204
Cancellation of
share premium
account - (9,342) 9,342 - - - - -
New share issue
(Ordinary shares) 4 310 - - - - - 314
Expenses of share
issue (Ordinary
shares) - (11) - - - - - (11)
Share buybacks for
cancellation (1) - (49) 1 - - - (49)
Management fee
allocated to
capital - - - - (115) - - (115)
Change in accrual
in IFA commission - (25) 2 - - - - (23)
Revenue return
after tax - - - - - - (231) (231)
Dividends paid - - (601) - - - - (601)
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
28 February 2018 116 298 9,974 56 451 171 (936) 10,130
------------------- -------- -------- ------------------- --------------- --------- ----------- --------- --------
* These figures are audited.
CONDENSED BALANCE SHEET
AS AT 31 AUGUST 2018
(UNAUDITED)
31 August 2018 31 August 2017 28 February 2018*
Note GBP'000 GBP'000 GBP'000
---------------------------------------- ----- --------------- --------------- ------------------
Fixed assets
Investments 8 11,015 5,260 7,982
---------------------------------------- ----- --------------- --------------- ------------------
Current assets
Debtors 47 22 44
Cash at bank and on deposit 950 2,652 2,267
---------------------------------------- ----- --------------- --------------- ------------------
997 2,674 2,311
---------------------------------------- ----- --------------- --------------- ------------------
Creditors: amounts falling due within
one year
Creditors (130) (185) (142)
Bank overdraft - - -
---------------------------------------- ----- --------------- --------------- ------------------
(130) (185) (142)
---------------------------------------- ----- --------------- --------------- ------------------
Net current assets 867 2,489 2,169
---------------------------------------- ----- --------------- --------------- ------------------
Non-current liabilities
IFA trail commission (51) (23) (21)
---------------------------------------- ----- --------------- --------------- ------------------
Total net assets 11,831 7,726 10,130
---------------------------------------- ----- --------------- --------------- ------------------
Capital and reserves
Called-up share capital 6 146 88 116
Share premium account 2,644 7,164 298
Special reserve 9,516 676 9,974
Capital redemption reserve 56 55 56
Capital reserve - realised 483 492 451
Capital reserve - unrealised (3) 104 171
Revenue reserve (1,011) (853) (936)
Total shareholders' funds 11,831 7,726 10,130
Net asset value per new Ordinary share
- basic 4 81.10p 87.54p 87.00p
---------------------------------------- ----- --------------- --------------- ------------------
* These figures are audited. The notes form an integral part of
these condensed financial statements.
CONDENSED STATEMENT OF CASH FLOW
FOR TO THE PERIOD FROM 1 MARCH 2018 TO 31 AUGUST 2018
(UNAUDITED)
6 Months 6 Months 12 Months
Ended Ended Ended
31 August 31 August 28 February
2018 2017 2018*
Note GBP'000 GBP'000 GBP'000
----------------------------------------- ----- ---------- ---------- ------------
Cash flow from operating activities
Investment income received 33 25 67
Deposit interest received 2 1 2
Investment management fees paid (87) (33) (145)
Other cash payments (114) (138) (264)
----------------------------------------- ----- ---------- ---------- ------------
Net cash flow from operating activities 5 (166) (145) (340)
----------------------------------------- ----- ---------- ---------- ------------
Cash flow from investing activities
Purchase of investments (3,357) (370) (1,070)
Sale of investments 254 - 73
----------------------------------------- ----- ---------- ---------- ------------
Net cash flow from investing activities (3,103) (370) (997)
----------------------------------------- ----- ---------- ---------- ------------
Cash flow from financing activities
Shares issued 2,504 105 418
Expenses of share issues (90) (119) (127)
IFA trail commission (4) - (3)
Neptune-Calculus cash received - - 286
Expenses of Neptune-Calculus cash
transaction - - (102)
Share buybacks for cancellation (7) - (49)
Equity dividend paid 9 (451) (601) (601)
----------------------------------------- ----- ---------- ---------- ------------
Net cash flow from financing activities 1,952 (615) (178)
----------------------------------------- ----- ---------- ---------- ------------
Decrease in cash and cash equivalents (1,317) (1,130) (1,515)
----------------------------------------- ----- ---------- ---------- ------------
Opening cash and cash equivalents 2,267 3,782 3,782
Net cash decrease (1,317) (1,130) (1,515)
Closing cash and cash equivalents 950 2,652 2,267
----------------------------------------- ----- ---------- ---------- ------------
* These figures are audited. The notes form an integral part of these Accounts.
CONDENSED NOTES TO THE ACCOUNTS
1. Nature of Financial Information
The unaudited half-yearly financial information does not
constitute statutory financial statements as defined in Section 434
of the Companies Act 2006 and has not been reviewed nor audited by
the auditors. This information has been prepared on the basis of
the accounting policies used in the statutory financial statements
of the Company for the year ended 28 February 2018, and in
accordance with FRS 104. The statutory financial statements for the
year ended 28 February 2018, which contained an unqualified
auditors' report, have been lodged with the Registrar of Companies,
did not include a reference to any matters to which the auditor
drew attention by way of emphasis without qualifying the report and
did not contain statements under Section 498(2) or (3) of the
Companies Act 2006.
2. Return per Share
6 Months Ended 6 Months Ended 12 Months Ended
31 August 2018 31 August 2017 28 February 2018
Revenue Capital Total Revenue Capital Total Revenue Capital Total
pence pence pence pence pence pence pence pence pence
------------ -------- -------- ------ -------- -------- ------ -------- -------- ------
Return per
Ordinary
share (0.6) (1.1) (1.7) (1.7) (0.8) (2.5) (2.3) (0.4) (2.7)
New Ordinary shares
Revenue return per Ordinary share is based on the net revenue
loss on ordinary activities after taxation of GBP75,126 and on
13,278,121 Ordinary shares, being the weighted average number of
Ordinary shares in issue during the period.
Capital return per Ordinary share is based on the net capital
loss for the period of GBP141,757 and on 13,278,121 Ordinary
shares, being the weighted average number of Ordinary shares in
issue during the period.
Total return per Ordinary share is based on the net loss on
ordinary activities for the period of GBP216,883 and on 13,278,121
Ordinary shares, being the weighted average number of Ordinary
shares in issue during the period.
3. Taxation on Ordinary Activities
The estimated effective tax rate at the period end is 0 per
cent. This remains unchanged from the prior year end.
4. Net Asset Value per Share
31 August 31 August 28 February
2018 2017 2018
pence Pence Pence
Net asset value per new Ordinary
share 81.1 87.5 87.0
The basic net asset value per new Ordinary share is based on net
assets (including current period revenue) of GBP11,831,000 and on
14,588,859 Ordinary shares, being the number of new Ordinary shares
in issue at the period end.
5. Reconciliation of Net Profit before Tax to Cash Flow from
Operating Activities
31 August 31 August 28 February
2018 2017 2018
GBP'000 GBP'000 GBP'000
------------------------------------- ---------- ---------- ------------
Ordinary Share Fund
Loss on ordinary activities before
tax (217) (216) (273)
Loss/(gain) on investments 70 16 (73)
Increase in debtors (3) (8) (30)
Decrease/increase in creditors (16) 63 20
Increase in non current IFA trail
commission accruals - - 21
Neptune-Calculus costs included
in finance activities - - (8)
IFA commission costs included in
finance activities - - 3
------------------------------------- ---------- ---------- ------------
Cash flow from operating activities (166) (145) (340)
------------------------------------- ---------- ---------- ------------
6. Called up share capital
31 August
2018
Number GBP'000
---------------------------- ----------- ----------
Ordinary shares of 1p each 14,588,859 146
In April 2018 the Company issued 1,779,298 Ordinary shares for a
total consideration of GBP1,518,453. In August 2018, 1,176,844
shares were issued for total consideration of GBP985,254.
In August 2018, the Company bought back and cancelled 10,000
shares.
The D shares that were issued prior to 1 August 2017 ranked for
the dividend of 4.0 pence per share that was paid on 26 July 2018.
The D shares were renamed Ordinary shares on 1 August 2017.The
Ordinary shares subscribed for after 1 August 2017 were not
eligible for any dividends declared in respect of the Company's
year ended 28 February 2018.
Following the issues and cancellation noted above there were
14,588,859 Ordinary shares in issue as at 31 August 2018.
7. Contingent assets and contingent liabilities
There were no contingent assets or contingent liabilities in
existence at 31 August 2018 (31 August 2017: GBPnil, 28 February
2018: GBPnil).
8. Fair Value Hierarchy
Investments held at fair value through profit or loss are valued
in accordance with IPEV guidelines.
The valuation method used will be the most appropriate valuation
methodology for an investment within its market, with regard to the
financial health of the investment and the IPEV guidelines. As
required by the Standard, an analysis of financial assets and
liabilities, which identifies the risk of the Company's holding of
such items is provided. The Standard requires an analysis of
investments carried at fair value based on the reliability and
significance of the information used to measure their fair
value.
In order to provide further information on the valuation
techniques used to measure assets carried at fair value, we have
categorised the measurement basis into a "fair value hierarchy" as
follows:
- Quoted market prices in active markets - "Level 1"
Inputs to Level 1 fair values are quoted prices for identical
asset in an active market. Quoted in an active market in this
context means quoted prices are readily and regularly available and
those prices represent actual and regularly occurring market
transactions on an arm's length basis. The quoted price is usually
the current bid price. The Company's investments in AIM quoted
equities and money market funds are classified within this
category.
- Valued using models with significant observable market inputs - "Level 2"
Inputs to Level 2 fair values are inputs other than quoted
prices included within Level 1 that are observable for the asset,
either directly or indirectly.
- Valued using models with significant unobservable market inputs - "Level 3"
Inputs to Level 3 fair values are unobservable inputs for the
asset. Unobservable inputs may have been used to measure fair value
to the extent that observable inputs are not available, thereby
allowing for situations in which there is little, if any, market
activity for the asset at the measurement date (or market
information for the inputs to any valuation models). As such,
unobservable inputs reflect the assumptions the Company considers
that market participants would use in pricing the asset. The
Company's unquoted equities and loan stock are classified within
this category. Unquoted investments are valued in accordance with
the IPEVCA guidelines.
Level 1 Level 2 Level 3 Total
GBP'000 GBP'000 GBP'000 GBP'000
-------- -------- -------- --------
Ordinary Share Fund
Opening book cost 3,370 - 4,441 7,811
Opening unrealised appreciation/(depreciation) (115) - 286 171
-------- -------- -------- --------
Opening valuation 3,255 - 4,727 7,982
-------- -------- -------- --------
Movements in the period:
Purchase at cost 2,400 - 957 3,357
Sales - proceeds - - (254) (254)
Sales - realised losses on
sales - - 104 104
Unrealised losses realised - - - -
during the period
Decrease in unrealised appreciation/(depreciation) (61) - (113) (174)
-------- -------- -------- --------
Closing valuation 5,594 - 5,421 11,015
-------- -------- -------- --------
Closing book cost 5,770 - 5,248 11,018
Closing unrealised (depreciation)/appreciation (176) - 173 (3)
-------- -------- -------- --------
Closing valuation 5,594 - 5,421 11,015
-------- -------- -------- --------
During the period there were no transfers between Levels 1, 2 or
3.
9. Dividends
For the year to 28 February 2018, the Ordinary Share Fund
declared a final dividend of 4.0p per share on 11,274,917 eligible
shares amounting to GBP450,997. The dividend was paid on 26 July
2018.
10. Transactions with Related Parties
John Glencross, a Director of the Company, is considered to be a
related party due to his position as Chief Executive and a director
of Calculus Capital Limited, one of the Company's Investment
Managers.
Calculus Capital Limited receives an investment manager's fee
from the Company. For the 6 months to 31 August 2018, Calculus
Capital Limited earned GBP95,748 (31 August 2017: GBP69,732; 28
February 2018: GBP154,089). Calculus Capital Limited also earned a
company secretarial fee of GBP7,500 (31 August 2017: GBP9,000; 28
February 2018: GBP18,000).
Calculus Capital Limited has taken on the expenses cap from 15
December 2015. For the 6 months to 31 August 2018, Calculus Capital
Limited contributed GBP15,204 (31 August 2017: GBPnil; 28 February
2018: GBP26,435).
At 31 August 2018, there was GBP55,566 owed to Calculus Capital
Limited (31 August 2017: GBP78,732; 28 February 2018:
GBP46,810).
11. Transactions with Investment Managers
John Glencross, a Director of the Company, is considered to be a
related party due to his position as Chief Executive and a director
of Calculus Capital Limited, the Company's Investment Manager. He
does not receive any remuneration from the Company. He is a
director of Terrain Energy Limited.
Calculus Capital Limited receives a fee from certain portfolio
companies. In the year the 31 August 2018, Calculus Capital charged
a monitoring fee to Air Leisure Group Limited, Antech Limited,
Arcis Biotechnology Holdings Limited, Cornerstone Brands Limited,
Duvas Technologies Limited, Every1Mobile Limited, Microenergy
Generation Services Limited, Mologic Limited, Open Energy Market
Limited, Origin Broadband Limited, Park Street Shipping Limited,
Quai Administration Services, Solab Group Limited, Synpromics
Limited, Terrain Energy Limited, The One Place Capital Limited,
Tollan Energy Limited and Weeding Technologies Limited.
Calculus Capital Limited charged a fee for the provision of a
director to Air Leisure Group Limited, Cornerstone Brands Limited,
Every1Mobile Limited, Open Energy Market, Origin Broadband Limited,
Pico's Limited, Terrain Energy Limited and Weeding Technologies
Limited.
Calculus Capital Limited charged an arrangement fee for certain
portfolio companies. In the year 31 August 2018 Calculus Capital
Limited charged a fee to CloudTrade Technologies Limited, Duvas
Technologies Limited, Oxford Biotherapeutics, Mologic Limited and
Pico's Limited.
Calculus Capital Limited also charged Terrain Energy Limited for
the provision of office support services.
The amount received by Calculus Capital which relates to the
Company's investment was GBP1,189 (28 February 2018: GBP1,578; 31
August 2017: GBP667) from Air Leisure Group Limited, GBP507 (28
February 2018: GBP972; 31 August 2017: GBP486) from AnTech Limited,
GBP94 (28 February 2018: GBP87; 31 August 2017 GBPnil) from Arcis
Biotechnology Holdings, GBPnil (28 February 2018: GBP5,172; 31
August 2017: GBP5,172) from Blu Wireless Technology Limited,
GBP6,000 (28 February 2018: GBPnil; 31 August 2017: GBPnil) from
CloudTrade Technologies Limited, GBP1,560 (28 February 2018:
GBP5,780; 31 August 2017: GBP4,500) from Cornerstone Brands
Limited, GBP6,249 (28 February 2018: GBPnil; 31 August 2017:
GBPnil) from Duvas Technologies Limited, GBP1,364 (28 February
2018: GBP6,459; 31 August 2017: GBPnil) from Every1Mobile Limited,
GBP967 (28 February 2018: GBP1,734; 31 August 2017: GBP788) from
MicroEnergy Generation Services Limited, GBP6,177 (28 February
2018: GBPnil; 31 August 2017: GBPnil) from Mologic Limited,
GBP1,155 (28 February 2018: GBP5,999; 31 August 2017: GBPnil) from
Open Energy Market Limited, GBP663 (28 February 2018: GBP2,544; 31
August 2017: GBP2,259) from Origin Broadband Limited, GBP5,999 (28
February 2018: GBPnil; 31 August 2017: GBPnil) from Oxford
Biotherapeutics Limited, GBP475 (28 February 2018: GBP836; 31
August 2017: GBP357) from Park Street Shipping Limited, GBP4,638
(28 February 2018: GBP318; 31 August 2017: GBP159) from Pico's
Limited, GBP559 (28 February 2018: GBP3,122; 31 August 2017:
GBP2,671) from Quai Administration Services Limited, GBP2,093 (28
February 2018: GBP2,906; 31 August 2017: GBP887) from Solab Group
Limited, GBP1,659 (28 February 2018: GBP1,094; 31 August 2017:
GBP415) from Terrain Energy Limited, GBP348 (28 February 2018:
GBP786; 31 August 2017: GBP568) from The One Place Capital Limited,
GBP837 (28 February 2018: GBP1,659; 31 August 2017: GBP822) from
Tollan Energy Limited, GBP145 (28 February 2018: GBP131; 31 August
2017: GBPnil) from Synpromics Limited and GBP1,177 (28 February
2018: GBP1,960; 31 August 2017: GBP667) from Weeding Technologies
Limited.
12. Post balance sheet events
Other than the sale of the Company's holding in Origin Broadband
Limited and investments in MIP Diagnostics Limited and C4X
Discovery Holdings plc, there have been no post balance sheet
events.
COMPANY INFORMATION
Directors Fund Administrator
Michael O'Higgins (Chairman) Link Alternative Fund Administrators
Limited
Kate Cornish-Bowden Beaufort House
John Glencross 51 New North Road
Steven Meeks Exeter EX4 4EP
Diane Seymour-Williams
Registered Office Auditors
104 Park Street Grant Thornton UK LLP
London 30 Finsbury Square
W1K 6NF London EC2P 2YU
Telephone: 020 7493 4940
Broker
Company Number Nplus1 Singer Advisory LLP
07142153 One Hanover Street
London W1S 1YZ
Venture Capital Investments Manager Registrars
And Company Secretary
Calculus Capital Limited The City Partnership (UK) Limited
104 Park Street 110 George Street
London W1K 6NF Edinburgh
Telephone: 020 7493 4940 EH2 4LH
Website: www.calculuscapital.com Telephone: 0131 243 7210
Sponsor
Beaumont Cornish Limited
29 Wilson Street
London EC2M 2SJ
Telephone: 0207 628 3396
Legal Entity Identifier: 2138005SMDWLMMNPVA90
Printed copies of the Calculus VCT plc Half Yearly Report for
the six months ended 31 August 2018 have not been posted to
shareholders. However, a copy can be found on the following
website: http://www.calculuscapital.com/calculus-vct/
For further information, please contact:
Calculus Capital Limited
Telephone: 020 7493 4940
Neither the contents of the Company's website nor the contents
of any website accessible from hyperlinks on this announcement (or
any other website) are incorporated into, or form part of, this
announcement.
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IR PGGUPUUPRGAW
(END) Dow Jones Newswires
October 23, 2018 11:32 ET (15:32 GMT)
Calculus Vct (LSE:CLC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calculus Vct (LSE:CLC)
Historical Stock Chart
From Sep 2023 to Sep 2024